Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OASIS: Phase II Trial of OrAl SM-88 in Patients With Metastatic Hormone Receptor-posItive HER2-negative (HR+/HER2-) breaSt Cancer

NCT04720664 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT04720664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04720664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OASIS: Phase II Trial of OrAl SM-88 in Patients With Metastatic Hormone Receptor-posItive HER2-negative (HR+/HER2-) breaSt Cancer
Lead sponsor
Georgetown University
Phase
Phase 2
Overall status
Terminated
Start date
September 22, 2021
Completion date
February 10, 2023
Enrollment
11 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hormone receptor positive breast carcinoma, metastatic breast cancer